AUTHORS
Krina Patel Jr, MD, MSc, David Berz, MD2, Mitul Gandhi, MD3, Krish Patel, MD4, John McKay, DO5, Megan Shelby, MS6, Matthew Collinson-Pautz, PhD7, Austin Bigley, PhD8, Mark Frohlich, MD9, Dheepak Kanagavel10, Aimee Merino, MD, PhD11
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Valkyrie Clinical Trials, Los Angeles, California, United States
3 Virginia Cancer Specialists, Manassas, Virginia, United States
4 Sarah Cannon Research Institute, Nashville, Tennessee, United States
5 Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
6 Indapta Therapeutics, Houston, Texas, United States
7 Indapta Therapeutics, Houston, Texas, United States
8 Indapta Therapeutics, Houston, Texas, United States
9 Indapta Therapeutics, Houston, Texas, United States
10 Sanofi, R&D, Vitry-sur-Seine, France
11 The University of Minnesota, Minneapolis, Minnesota, United States
ABSTRACT
Introduction
Patients with multiple myeloma (MM) who have exposure or resistance to the major classes of therapy, proteasome inhibitors (PI), immunomodulatory drugs (IMiD), anti-CD38 monoclonal antibodies (mAb), and CAR-T or T-cell engagers, have a poor prognosis and limited therapeutic options. Relapse in these highly refractory patients highlights a profound unmet clinical need. IDP-023 is a cryopreserved, allogeneic, non-engineered NK cell product enriched for FcɛR1γ-deficient g-NK cells. Through innate epigenetic reprogramming, g-NK cells exhibit markedly enhanced antibody-dependent cellular cytotoxicity compared to conventional NK cells. Here we report complete safety, efficacy, recommended Phase 2 dose (RP2D), and translational findings of a multicenter, first-in-human Phase 1/2 dose-escalation study of IDP-023 (NCT06119685).
Methods
In a Phase 1/2 dose-escalation and dose-expansion study of IDP-023 administered as a single agent and in combination with or without anti-CD38 mAb, eligible patients had r/r MM and were triple-class (1×PI, 1×IMiD, 1×anti-CD38 mAb) exposed. Patients received fludarabine (30 mg/m2/day) and cyclophosphamide (400 mg/m2/day) conditioning, followed by 1-3 IDP-023 doses/cycle administered weekly or every other day (Q2D) with or without low-dose IL-2 (6 MIU). Doses evaluated: 5×109, 1×1010, and 2×1010 cells/dose. Primary objectives: determine maximum tolerated dose/maximum assessed dose (MAD), RP2D, and overall safety/tolerability. Clinical responses were assessed by International Myeloma Working Group criteria. Translational analyses included serum cytokines and bone marrow CyTOF immunophenotyping.
Results
As of July 22, 2026, 25 r/r MM patients have been enrolled with dose-escalation and follow-up complete. Nine patients received IDP-023 monotherapy and 16 patients received IDP-023 in combination with anti-CD38 mAb (isatuximab N=12, daratumumab N=4). The MAD was 2×1010 cells. The RP2D was determined to be 1×10¹⁰ cells Q2D×3 + isatuximab. Isatuximab (I) cohort patients were heavily pre-treated: 100% were anti-CD38 mAb refractory, 92% were triple-class refractory, 83% had prior BCMA-targeted therapy, 58% were penta-refractory. 83% had high-/ultra-high-risk cytogenetics. Median number of prior lines was 7 (range 4-17). Of the 11 efficacy-evaluable I cohort patients, the overall response rate (ORR) was 36% (4/11) and the clinical benefit rate (CBR) was 55% (6/11). In this CD38-refractory setting expected ORR and CBR for isatuximab alone was 0% and 3%, respectively (Mikhael, 2021). The median PFS (mPFS) was 6.3 months (95% CI, 2 to NA, N=12) compared to 2.2 months mPFS for IDP-023 monotherapy and 1.6 months mPFS for isatuximab monotherapy (Mikhael, 2021).
Notably, 1 patient with penta-drug refractory, ultra-high-risk cytogenetics, extramedullary disease treated with 10 prior lines of therapy (including CAR-T and TCE) achieved a stringent complete response (sCR) that remained ongoing at last follow-up (Day 395).
No dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or Grade ≥3 cytokine release syndrome (CRS) were observed. No treatment-related discontinuations occurred. Grade ≥3 adverse events were predominantly hematologic, transient and consistent with the conditioning regimen.
Serum GzmB/IFN-γ/TNF-α increased post-IDP-023, consistent with NK cell activation. Bone marrow analyses exhibited tumor microenvironment (TME) remodeling post-IDP-023 with reduction of myeloid-derived suppressor cells and increased CD8+ and γδ T cells.
Conclusions
IDP-023 + isatuximab demonstrates a compelling efficacy signal with a manageable safety profile in heavily pretreated, high-risk r/r MM. The 36% ORR, 55% CBR, and 6.3 months mPFS, including a durable sCR beyond 1 year in a patient with high-risk features and exhaustive prior therapy, are clinically meaningful in this setting and are consistent with our preclinical hypothesis that IDP-023 + anti-CD38 mAb can restore sensitivity in patients who are anti-CD38 mAb refractory. The absence of DLTs, Grade ≥3 CRS or ICANS, with no treatment-related discontinuations, underscores the tolerability advantage of off-the-shelf IDP-023 cell therapy over current T-cell-based approaches. Mechanistic biomarker data demonstrate favorable TME remodeling that may underlie the durability of responses. Overall, these encouraging data support continued development of IDP-023 + isatuximab in this high unmet clinical need patient population.
DISCLOSURES
Krina Patel Jr, MD, MSc: Janssen, Legend Biotech, AstraZeneca, AbbVie, Regeneron, Merck, Genentech, Takeda, Caribou Biosciences, and Pfizer - Honoraria; JnJ/Janssen - Honoraria; Bristol Myers Squibb - Honoraria; Bristol Myers Squibb - Research Funding; Takeda - Research Funding; Celgene/BMS - Research Funding; Kite, a Gilead Company - Research Funding; Nektar and Allogene - Research Funding; Sanofi - Research Funding; Bristol Myers Squibb - Research Funding; Indapta - Research Funding; JnJ/Janssen - Research Funding; AbbVie - Consultancy (Includes expert testimony); Oricell - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Kite, a Gilead Company and Novartis - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Janssen, Legend Biotech, AstraZeneca, AbbVie, Regeneron, Merck, Genentech, Takeda, Caribou Biosciences, and Pfizer - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Poseida - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Kite, a Gilead Company - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Celgene/BMS - Consultancy (Includes expert testimony); JnJ/Janssen - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Celgene/BMS - Membership on a Board/Advisory Committee